CJC-1295 (NO DAC)

CJC-1295 without DAC is another version of the synthetic peptide designed to stimulate growth hormone (GH) release, similar to the DAC version. However, this form has a much shorter half-life, generally around 30 minutes, because it lacks the Drug Affinity Complex (DAC) that extends the peptide’s stability and bioavailability.

This version is often used in research settings where precise timing and pulsatile GH release are desired.

How It Works

CJC-1295 without DAC works by mimicking natural growth hormone-releasing hormone (GHRH). When administered, it binds to receptors in the pituitary gland, triggering the release of growth hormone. Due to its short half-life, it produces a rapid but transient spike in GH levels.

Because of its short activity window, it is typically combined with growth hormone secretagogues (like GHRP-6 or Ipamorelin) to create a synergistic effect, amplifying the natural release of GH in a pulsatile manner.

Potential Benefits

The benefits of CJC-1295 without DAC mirror those of the DAC version, but with some key differences due to its shorter half-life and administration frequency.

1. Pulsatile Growth Hormone Release

   • Mimics natural GH secretion patterns more closely.
   • May reduce the risk of GH desensitization over time.

2. Muscle Growth and Fat Loss

   • Increased GH levels support muscle repair and fat metabolism.
   • Promotes lean body mass development.

3. Improved Recovery

   • Faster recovery from physical strain or injury due to enhanced GH availability.

4. Anti-Aging Effects

   • Similar potential for improving skin elasticity, bone density, and joint health.

5. Sleep and Energy

   • Boosts deep sleep and energy levels.

Potential Side Effects

Like CJC-1295 with DAC, this version carries potential side effects, including:

• Water retention.
• Mild joint pain.
• Numbness or tingling in extremities.
• Headaches or fatigue after injection.

The short half-life reduces prolonged exposure, which might minimize the risk of long-term side effects. However, the need for more frequent injections can increase the likelihood of local injection site reactions.

Dosage and Administration

Due to its shorter half-life, CJC-1295 without DAC typically requires more frequent administration to maintain consistent GH release. It is generally administered via subcutaneous injection.

Typical Dosages:

• 100–200 mcg per injection.
• Administered 1–3 times daily, often before bed or post-workout to coincide with natural GH peaks.